GB9606452D0 - Organic compounds - Google Patents
Organic compoundsInfo
- Publication number
- GB9606452D0 GB9606452D0 GBGB9606452.2A GB9606452A GB9606452D0 GB 9606452 D0 GB9606452 D0 GB 9606452D0 GB 9606452 A GB9606452 A GB 9606452A GB 9606452 D0 GB9606452 D0 GB 9606452D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- organic compounds
- deoxyspergualine
- ctla4
- azathioprine
- cyclosporin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract 1
- 208000024248 Vascular System injury Diseases 0.000 abstract 1
- 208000012339 Vascular injury Diseases 0.000 abstract 1
- 206010053648 Vascular occlusion Diseases 0.000 abstract 1
- 229960002170 azathioprine Drugs 0.000 abstract 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 abstract 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 abstract 1
- 229960004866 mycophenolate mofetil Drugs 0.000 abstract 1
- 229960000951 mycophenolic acid Drugs 0.000 abstract 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 229960001967 tacrolimus Drugs 0.000 abstract 1
- 230000008719 thickening Effects 0.000 abstract 1
- 208000021331 vascular occlusion disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (42)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9606452.2A GB9606452D0 (en) | 1996-03-27 | 1996-03-27 | Organic compounds |
| IDP970980A ID17195A (id) | 1996-03-27 | 1997-03-25 | Pemakaian turunan-turunan rapamisin pada vaskulofati dan senotransplantasi |
| MYPI97001258A MY117798A (en) | 1996-03-27 | 1997-03-25 | Use of a rapamycin derivative in vasculopathies and xenotransplantation |
| NZ331463A NZ331463A (en) | 1996-03-27 | 1997-03-26 | Use of rapamycin derivatives in vasculopathies and xenotransplantation |
| IL12581297A IL125812A (en) | 1996-03-27 | 1997-03-26 | Pharmaceutical compositions comprising 40-o-(2-hydroxyethyl)-rapamycin for use in vasculopathies and xenotransplantation and the novel combination of the compound with mycophenolic acid, mycophenolate mofetil or ctla4-ig |
| TR1998/01919T TR199801919T2 (xx) | 1996-03-27 | 1997-03-26 | Rapamisin t�revlerinin damar hastal�klar� ve yabanc� doku naklinde kullan�m�. |
| KR1020077008212A KR20070083654A (ko) | 1996-03-27 | 1997-03-26 | 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도 |
| AU22918/97A AU716514B2 (en) | 1996-03-27 | 1997-03-26 | Use of rapamycin derivatives in vasculopathies and xenotransplantation |
| PL97328659A PL187732B1 (pl) | 1996-03-27 | 1997-03-26 | Zastosowanie pochodnej rapamycyny w waskulopatii i przeszczepach międzygatunkowych |
| PT80173362T PT2008657E (pt) | 1996-03-27 | 1997-03-26 | Uso de derivados da rapamicina em vasculopatias |
| JP9532077A JP2000507226A (ja) | 1996-03-27 | 1997-03-26 | 血管疾病および異種移植におけるラパマイシン誘導体の使用 |
| ES97915441T ES2184078T3 (es) | 1996-03-27 | 1997-03-26 | Uso de derivados de rapamicina en vasculopatias y xenotrasplantes. |
| SI9730405T SI0893996T1 (en) | 1996-03-27 | 1997-03-26 | Use of a rapamycin derivative in vasculopathies and xenotransplantation |
| ES08017336T ES2421455T3 (es) | 1996-03-27 | 1997-03-26 | Uso de derivados de rapamicina en vasculopatías |
| PCT/EP1997/001548 WO1997035575A1 (en) | 1996-03-27 | 1997-03-26 | Use of rapamycin derivatives in vasculopathies and xenotransplantation |
| CZ19983070A CZ292483B6 (cs) | 1996-03-27 | 1997-03-26 | Farmaceutická kompozice obsahující 40-O-(2-hydroxy)ethylrapamycin |
| AT97915441T ATE224194T1 (de) | 1996-03-27 | 1997-03-26 | Verwendung eines rapamycinderivates zur behandlung von gefäss erkrankungen und xenotransplantationen |
| EP97915441A EP0893996B1 (en) | 1996-03-27 | 1997-03-26 | Use of a rapamycin derivative in vasculopathies and xenotransplantation |
| CA2247275A CA2247275C (en) | 1996-03-27 | 1997-03-26 | Use of rapamycin derivatives in vasculopathies and xenotransplantation |
| DK97915441T DK0893996T3 (da) | 1996-03-27 | 1997-03-26 | Anvendelse af et rapamycinderivat til behandling af karsygdomme og xenotransplantationer |
| DK08017336.2T DK2008657T3 (da) | 1996-03-27 | 1997-03-26 | Anvendelse af rapamycinderivater ved karforandringer |
| PT97915441T PT893996E (pt) | 1996-03-27 | 1997-03-26 | Uso de derivados de rapamicina em vasculopatias e em xenotransplantacao |
| RU98119312/14A RU2214247C2 (ru) | 1996-03-27 | 1997-03-26 | Применение производных рапамицина при вазопатиях и ксенотрансплантации |
| HU0001267A HU226422B1 (en) | 1996-03-27 | 1997-03-26 | Use of rapamycin derivatives for the preparation of pharmaceutical compositions treating vasculopathies |
| SI9730801T SI2008657T1 (sl) | 1996-03-27 | 1997-03-26 | Uporaba rapamicinskih derivatov pri vaskulopatijah |
| CN97193278A CN1124135C (zh) | 1996-03-27 | 1997-03-26 | 雷帕霉素衍生物在血管病和异种移植中的应用 |
| KR1020057005463A KR100836971B1 (ko) | 1996-03-27 | 1997-03-26 | 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도 |
| DE69715611T DE69715611T2 (de) | 1996-03-27 | 1997-03-26 | Verwendung eines rapamycinderivates zur behandlung von gefäss erkrankungen und xenotransplantationen |
| SK1327-98A SK284343B6 (sk) | 1996-03-27 | 1997-03-26 | Použitie 40-O-(2-hydroxy)etyl-rapamycínu |
| EP01116262A EP1149581A3 (en) | 1996-03-27 | 1997-03-26 | Use of rapamycin derivatives in vasculopathies and xenotransplantation |
| BR9708358A BR9708358A (pt) | 1996-03-27 | 1997-03-26 | Uso de derivados de rapamicina em vasculopatias e xenotransplantes |
| HK99103744.5A HK1018688B (en) | 1996-03-27 | 1997-03-26 | Use of rapamycin derivatives in vasculopqthies and xenotransplantation |
| EP08017336.2A EP2008657B1 (en) | 1996-03-27 | 1997-03-26 | Use of rapamycin derivatives in vasculopathies |
| ZA972719A ZA972719B (en) | 1996-03-27 | 1997-03-27 | Use of rapamycin derivatives in vasculopathies and xenotransplantations |
| NO19984340A NO316667B1 (no) | 1996-03-27 | 1998-09-18 | Anvendelsen av 40-O-(2-hydroksy)etyl-rapamycin ved fremstilling av medikamenter |
| US09/712,359 US6384046B1 (en) | 1996-03-27 | 2000-11-14 | Use of 40-O-(2-hydroxy)ethylrapamycin for treatment of restenosis and other disorders |
| US10/092,639 US20020127248A1 (en) | 1996-03-27 | 2002-03-07 | Use of rapamycin derivatives in vasculop atheis and xenotransplantation |
| CY0400004A CY2404B1 (en) | 1996-03-27 | 2004-01-08 | Use of rapamycin derivatives in vasculopathies andxenotransplantation. |
| JP2008314494A JP5124431B2 (ja) | 1996-03-27 | 2008-12-10 | 血管疾病および異種移植におけるラパマイシン誘導体の使用 |
| US12/715,007 US20100152105A1 (en) | 1996-03-27 | 2010-03-01 | Use of rapamycin derivatives in chronic rejection |
| US13/357,199 US20120177690A1 (en) | 1996-03-27 | 2012-01-24 | Use of rapamycin derivatives in vasculopathies and xenotransplantation |
| US14/197,368 US20140187574A1 (en) | 1996-03-27 | 2014-03-05 | Use of rapamycin derivatives in vasculopathies and xenotransplantation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9606452.2A GB9606452D0 (en) | 1996-03-27 | 1996-03-27 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB9606452D0 true GB9606452D0 (en) | 1996-06-05 |
Family
ID=10791127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB9606452.2A Pending GB9606452D0 (en) | 1996-03-27 | 1996-03-27 | Organic compounds |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US6384046B1 (https=) |
| EP (3) | EP0893996B1 (https=) |
| JP (2) | JP2000507226A (https=) |
| KR (2) | KR100836971B1 (https=) |
| CN (1) | CN1124135C (https=) |
| AT (1) | ATE224194T1 (https=) |
| AU (1) | AU716514B2 (https=) |
| BR (1) | BR9708358A (https=) |
| CA (1) | CA2247275C (https=) |
| CY (1) | CY2404B1 (https=) |
| CZ (1) | CZ292483B6 (https=) |
| DE (1) | DE69715611T2 (https=) |
| DK (2) | DK0893996T3 (https=) |
| ES (2) | ES2184078T3 (https=) |
| GB (1) | GB9606452D0 (https=) |
| HU (1) | HU226422B1 (https=) |
| ID (1) | ID17195A (https=) |
| IL (1) | IL125812A (https=) |
| MY (1) | MY117798A (https=) |
| NO (1) | NO316667B1 (https=) |
| NZ (1) | NZ331463A (https=) |
| PL (1) | PL187732B1 (https=) |
| PT (2) | PT2008657E (https=) |
| RU (1) | RU2214247C2 (https=) |
| SI (1) | SI2008657T1 (https=) |
| SK (1) | SK284343B6 (https=) |
| TR (1) | TR199801919T2 (https=) |
| WO (1) | WO1997035575A1 (https=) |
| ZA (1) | ZA972719B (https=) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606452D0 (en) * | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| EP1208847B8 (en) | 1996-07-30 | 2007-02-14 | Novartis AG | Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions |
| US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US20030129215A1 (en) * | 1998-09-24 | 2003-07-10 | T-Ram, Inc. | Medical devices containing rapamycin analogs |
| JP2002544167A (ja) * | 1999-05-10 | 2002-12-24 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| US20070032853A1 (en) † | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
| US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
| US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
| US20070141107A1 (en) * | 2000-03-15 | 2007-06-21 | Orbusneich Medical, Inc. | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device |
| US20030229393A1 (en) * | 2001-03-15 | 2003-12-11 | Kutryk Michael J. B. | Medical device with coating that promotes cell adherence and differentiation |
| US8460367B2 (en) * | 2000-03-15 | 2013-06-11 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
| US20070055367A1 (en) * | 2000-03-15 | 2007-03-08 | Orbus Medical Technologies, Inc. | Medical device with coating that promotes endothelial cell adherence and differentiation |
| ATE362382T1 (de) | 2000-03-15 | 2007-06-15 | Orbusneich Medical Inc | Beschichtung welche ein anhaften von endothelzellen stimuliert |
| US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
| US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
| US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
| US7300662B2 (en) | 2000-05-12 | 2007-11-27 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
| US20050002986A1 (en) * | 2000-05-12 | 2005-01-06 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
| US20020013335A1 (en) * | 2000-06-16 | 2002-01-31 | American Home Products Corporation | Method of treating cardiovascular disease |
| US6670355B2 (en) * | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
| EP1709974A3 (en) * | 2000-06-16 | 2006-12-06 | Wyeth | Method of treating cardiovascular disease using rapamycin |
| AU9486901A (en) | 2000-09-29 | 2002-04-08 | Cordis Corp | Coated medical devices |
| PL409579A1 (pl) * | 2001-02-19 | 2015-03-02 | Novartis Ag | Leczenie raka |
| US8741378B1 (en) | 2001-06-27 | 2014-06-03 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device |
| US7682387B2 (en) * | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| US6939376B2 (en) | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| CA2476832A1 (en) * | 2002-02-22 | 2003-08-28 | Prophy Med Ab | Use of an inhibitor or antagonist against tissue factor |
| US20040024450A1 (en) * | 2002-04-24 | 2004-02-05 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| AU2003241515A1 (en) * | 2002-05-20 | 2003-12-12 | Orbus Medical Technologies Inc. | Drug eluting implantable medical device |
| US8109987B2 (en) | 2003-04-14 | 2012-02-07 | Tryton Medical, Inc. | Method of treating a lumenal bifurcation |
| US7279174B2 (en) * | 2003-05-08 | 2007-10-09 | Advanced Cardiovascular Systems, Inc. | Stent coatings comprising hydrophilic additives |
| US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
| US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| US9114198B2 (en) | 2003-11-19 | 2015-08-25 | Advanced Cardiovascular Systems, Inc. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
| EP2946666B1 (en) * | 2004-04-30 | 2017-11-15 | OrbusNeich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods of using same |
| WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
| US8709469B2 (en) | 2004-06-30 | 2014-04-29 | Abbott Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
| US7901451B2 (en) * | 2004-09-24 | 2011-03-08 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| US20060194829A1 (en) * | 2004-12-20 | 2006-08-31 | Clackson Timothy P | Therapeutic materials and methods |
| CA2629714A1 (en) | 2005-11-14 | 2007-05-24 | Ariad Gene Therapeutics, Inc. | Administration of an mtor inhibitor to treat patients with cancer |
| CN101340859B (zh) * | 2005-11-17 | 2010-12-15 | 路嘉株式会社 | 用于制备在对身体的医疗手术中使用的插入物的方法 |
| US20070173923A1 (en) * | 2006-01-20 | 2007-07-26 | Savage Douglas R | Drug reservoir stent |
| EP2083834B1 (en) | 2006-09-13 | 2017-06-21 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
| US20080097591A1 (en) | 2006-10-20 | 2008-04-24 | Biosensors International Group | Drug-delivery endovascular stent and method of use |
| US8067055B2 (en) * | 2006-10-20 | 2011-11-29 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method of use |
| US20080103584A1 (en) | 2006-10-25 | 2008-05-01 | Biosensors International Group | Temporal Intraluminal Stent, Methods of Making and Using |
| KR100930167B1 (ko) * | 2007-09-19 | 2009-12-07 | 삼성전기주식회사 | 초광각 광학계 |
| US8661630B2 (en) | 2008-05-21 | 2014-03-04 | Abbott Cardiovascular Systems Inc. | Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer |
| CA2705764C (en) | 2007-11-14 | 2016-08-02 | Biosensors International Group, Ltd. | Automated stent coating apparatus and method |
| WO2009089549A1 (en) * | 2008-01-11 | 2009-07-16 | Massachusetts Eye & Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
| EP2352459A4 (en) * | 2008-10-03 | 2013-09-25 | Elixir Medical Corp | MACROCYCLIC LACTON COMPOUNDS AND METHOD FOR THEIR USE |
| US8382818B2 (en) | 2009-07-02 | 2013-02-26 | Tryton Medical, Inc. | Ostium support for treating vascular bifurcations |
| US8685433B2 (en) | 2010-03-31 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
| UA104738C2 (ru) | 2011-05-18 | 2014-03-11 | Олег Миколайович Лазаренко | Композиция для повышения биосовместимости имплантатов и клеток для трансплантации с организмом реципиента и способ ее приготовления |
| CN102268015B (zh) * | 2011-08-30 | 2013-08-28 | 成都摩尔生物医药有限公司 | 一种依维莫司的合成方法 |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| KR101723265B1 (ko) | 2013-08-16 | 2017-04-04 | 가톨릭대학교 산학협력단 | mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 |
| CN105792775B (zh) | 2013-09-24 | 2019-02-19 | 吉纳生命科学公司 | 用于细胞植入物的气体处理的系统 |
| US10307370B2 (en) | 2013-10-08 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| KR20160120739A (ko) | 2014-02-11 | 2016-10-18 | 램 테라퓨틱스, 인코포레이티드 | 림프관평활근종증의 치료를 위한 라파마이신 |
| US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| DK3125875T3 (da) | 2014-04-04 | 2023-07-24 | Ai Therapeutics Inc | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande |
| KR20170095807A (ko) | 2014-10-07 | 2017-08-23 | 램 테라퓨틱스, 인코포레이티드 | 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제 |
| MA40910A (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| WO2016130645A1 (en) | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| WO2018031789A1 (en) | 2016-08-10 | 2018-02-15 | The Board Of Regents Of The University Of Texas System | Topical rapamycin therapy |
| US12453624B2 (en) | 2016-09-19 | 2025-10-28 | Biotronik Ag | Polymer-free drug eluting vascular stents |
| MX2019005676A (es) | 2016-11-15 | 2019-09-10 | Giner Life Sciences Inc | Dispositivo percutáneo de difusión de gases adecuado para su uso con un implante subcutáneo. |
| CN109996569B (zh) | 2016-12-22 | 2022-05-03 | 百多力股份公司 | 用于医疗装置的药物释放涂层及其制备方法 |
| JP7199632B2 (ja) | 2017-05-04 | 2023-01-06 | ガイナー，インク． | 堅牢なインプラント可能なガス送達装置ならびにそれを含む方法、システムおよび装置 |
| AR112834A1 (es) | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
| MX2021007247A (es) | 2018-12-18 | 2021-07-15 | Novartis Ag | Derivados de rapamicina. |
| BR112021016296A2 (pt) | 2019-02-20 | 2021-11-09 | Ai Therapeutics Inc | Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639724A (en) * | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
| US5364612A (en) * | 1991-05-06 | 1994-11-15 | Immunomedics, Inc. | Detection of cardiovascular lesions |
| ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| CA2086642C (en) * | 1992-01-09 | 2004-06-15 | Randall E. Morris | Method of treating hyperproliferative vascular disease |
| US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| CA2094858C (en) * | 1992-04-28 | 2004-06-15 | Robert D. Mitchell | Method of treating hyperproliferative vascular disease |
| US5747034A (en) * | 1992-07-09 | 1998-05-05 | Chiron Corporation | Methods and materials for the induction of T cell anergy |
| US5283257A (en) * | 1992-07-10 | 1994-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating hyperproliferative vascular disease |
| GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5912253A (en) * | 1993-12-17 | 1999-06-15 | Novartis Ag | Rapamycin derivatives |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US6265427B1 (en) * | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
| EP0833828B1 (en) * | 1995-06-09 | 2002-11-20 | Novartis AG | Rapamycin derivatives |
| GB9606452D0 (en) * | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
-
1996
- 1996-03-27 GB GBGB9606452.2A patent/GB9606452D0/en active Pending
-
1997
- 1997-03-25 MY MYPI97001258A patent/MY117798A/en unknown
- 1997-03-25 ID IDP970980A patent/ID17195A/id unknown
- 1997-03-26 CN CN97193278A patent/CN1124135C/zh not_active Expired - Lifetime
- 1997-03-26 DK DK97915441T patent/DK0893996T3/da active
- 1997-03-26 NZ NZ331463A patent/NZ331463A/en not_active IP Right Cessation
- 1997-03-26 EP EP97915441A patent/EP0893996B1/en not_active Revoked
- 1997-03-26 SI SI9730801T patent/SI2008657T1/sl unknown
- 1997-03-26 EP EP08017336.2A patent/EP2008657B1/en not_active Expired - Lifetime
- 1997-03-26 HU HU0001267A patent/HU226422B1/hu unknown
- 1997-03-26 PT PT80173362T patent/PT2008657E/pt unknown
- 1997-03-26 WO PCT/EP1997/001548 patent/WO1997035575A1/en not_active Ceased
- 1997-03-26 ES ES97915441T patent/ES2184078T3/es not_active Expired - Lifetime
- 1997-03-26 DE DE69715611T patent/DE69715611T2/de not_active Revoked
- 1997-03-26 IL IL12581297A patent/IL125812A/en not_active IP Right Cessation
- 1997-03-26 PL PL97328659A patent/PL187732B1/pl unknown
- 1997-03-26 AU AU22918/97A patent/AU716514B2/en not_active Expired
- 1997-03-26 RU RU98119312/14A patent/RU2214247C2/ru active
- 1997-03-26 JP JP9532077A patent/JP2000507226A/ja not_active Withdrawn
- 1997-03-26 TR TR1998/01919T patent/TR199801919T2/xx unknown
- 1997-03-26 EP EP01116262A patent/EP1149581A3/en not_active Withdrawn
- 1997-03-26 KR KR1020057005463A patent/KR100836971B1/ko not_active Expired - Lifetime
- 1997-03-26 KR KR1020077008212A patent/KR20070083654A/ko not_active Withdrawn
- 1997-03-26 PT PT97915441T patent/PT893996E/pt unknown
- 1997-03-26 AT AT97915441T patent/ATE224194T1/de not_active IP Right Cessation
- 1997-03-26 ES ES08017336T patent/ES2421455T3/es not_active Expired - Lifetime
- 1997-03-26 SK SK1327-98A patent/SK284343B6/sk not_active IP Right Cessation
- 1997-03-26 CZ CZ19983070A patent/CZ292483B6/cs not_active IP Right Cessation
- 1997-03-26 CA CA2247275A patent/CA2247275C/en not_active Expired - Lifetime
- 1997-03-26 DK DK08017336.2T patent/DK2008657T3/da active
- 1997-03-26 BR BR9708358A patent/BR9708358A/pt not_active Application Discontinuation
- 1997-03-27 ZA ZA972719A patent/ZA972719B/xx unknown
-
1998
- 1998-09-18 NO NO19984340A patent/NO316667B1/no not_active IP Right Cessation
-
2000
- 2000-11-14 US US09/712,359 patent/US6384046B1/en not_active Expired - Lifetime
-
2002
- 2002-03-07 US US10/092,639 patent/US20020127248A1/en not_active Abandoned
-
2004
- 2004-01-08 CY CY0400004A patent/CY2404B1/xx unknown
-
2008
- 2008-12-10 JP JP2008314494A patent/JP5124431B2/ja not_active Expired - Lifetime
-
2010
- 2010-03-01 US US12/715,007 patent/US20100152105A1/en not_active Abandoned
-
2012
- 2012-01-24 US US13/357,199 patent/US20120177690A1/en not_active Abandoned
-
2014
- 2014-03-05 US US14/197,368 patent/US20140187574A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB9606452D0 (en) | Organic compounds | |
| IL140137A (en) | Receptor bodies specifically binding tie-2 ligands | |
| PY0101639A (es) | Method of treating restenosis with rapamycin | |
| FI963101A7 (fi) | Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut | |
| ATE175198T1 (de) | N-acylierte trizyklische azaheteroringe verwendbar als vasopressin-antagonisten | |
| EA200001169A1 (ru) | Специфично связывающиеся молекулы для сцинтиграфии, содержащие их конъюгаты и терапевтический способ лечения ангиогенеза | |
| DE69003202D1 (de) | Hochfeste, hitzebeständige, niedrig legierte Stähle. | |
| DE69112007D1 (de) | Ferritischer, hitzebeständiger Gussstahl und Verfahren zu seiner Herstellung. | |
| DE69720241D1 (de) | Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen | |
| ATE485054T1 (de) | Pharmazeutische oder nährungsmittelzusammensetzung für die behandlung von pathologien die assoziert sind mit einem transplantatabstoss | |
| DE602004017838D1 (de) | Verfahren zur herstellung von 6-ä(4,5-dihydro-1h-imidazol-2-yl)amino-ü-7-methyl-1h-benzimidazol-4-carbonitrile und dessen bevorzugte salzform | |
| PH31426A (en) | 4-Amino derivatives of 5-substituted mycophenolic acid. | |
| RU97118099A (ru) | Способ лечения психопатологических синдромов пограничного уровня сосудисто- склеротического генеза | |
| DE50210279D1 (de) | Screeningverfahren mit bnpi und dnpi | |
| EP0446797A3 (en) | Synthetic peptides containing factor viia sequences and their use | |
| EP0791360A3 (en) | Treatment of septic shock with anti-TNF antibodies | |
| Pioli | Reactivation failure in infants: A processing analysis. | |
| RU96118013A (ru) | Способ реконструкции молочной железы | |
| White | DNA testing exposes whale trade. | |
| Bertschy et al. | Vulnerability to fluoxetine-induced indifference syndrome among opiate addicts: a case report. | |
| IT1241270B (it) | Procedimento per realizzare vaschette di contenimento per cuscini, particolarmente cuscini di sedili per autoveicoli. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 730 | Substitution of applicants allowed (sect. 30/1977) |